CONTERA PHARMA A/S: Financial statements 2020
CVR: 33062214
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -9,724,551 and a net result of DKK -12,258,975 compared with DKK -2,002,844 the year before. Equity in the 2020 report amounted to DKK 194,960,912. The solvency ratio was 96.8%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -9,724,551
- Profit/Loss
- DKK -12,258,975
- Equity
- DKK 194,960,912
- Total Assets
- DKK 201,325,856
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -9.7 mio. | -12.3 mio. | 195 mio. | 4 |
| 2019 | - | -1.2 mio. | -2 mio. | 17.8 mio. | 1 |
| 2018 | - | 1.5 mio. | -968 t. | 3.2 mio. | 2 |
| 2017 | - | 1.4 mio. | -419 t. | 1 mio. | 2 |
| 2016 | - | 3.1 mio. | 866 t. | 1.5 mio. | - |
Official annual report
How creditworthy is CONTERA PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 1, 2020, Thomas Nikolaj Sager is registered as adm. dir. of CONTERA PHARMA A/S.
As of December 1, 2020, John Bondo Hansen has stepped down as adm. dir. of CONTERA PHARMA A/S.
As of November 13, 2020, Eun Ju Kim has joined the board of directors of CONTERA PHARMA A/S.
As of November 13, 2020, Sang Hoon Kim has left the board of directors of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2019. Gross profit came to DKK -1,249,644, and the net result was DKK -2,002,844.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.